Gilead leukemia drug trial unblinded early due to success

Nov 16 (Reuters) - A late stage trial of a Gilead Sciences drug in previously treated patients with a particular type of leukemia was unblinded early after independent monitors determined the medicine provided significant benefit in delaying worsening of the disease, the company said on Monday.